Navigation Links
Avanir Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Date:5/31/2011

ALISO VIEJO, Calif., May 31, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the Jefferies 2011 Global Healthcare Conference in New York, NY.

  • Location: Grand Hyatt, New York, NY
  • Presentation date: Tuesday June 7, 2011
  • Presentation time: 12:15 p.m. Eastern Time

A live webcast and 30-day archive of this presentation will be available at http://www.avanir.com.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR™ is a trademark owned by Avanir Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners

©2011 Avanir Pharmaceuticals, Inc. All Rights Reserved.


'/>"/>
SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AVANIR to Present at the Wedbush Life Sciences Conference
2. AVANIR to Present at the Canaccord Genuity Growth Conference
3. AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
8. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
9. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
10. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
11. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ ... report to their offering. The ... a CAGR of 22.7% from 2014 to 2019. Factors ... treatment, growing adoption of companion diagnostics by the pharmaceutical ...
(Date:9/18/2014)... -- U.S. biotech company Kultevat has strengthened its ... developed by the Donald Danforth Plant Science Center ... applications in production of natural rubber in Taraxicum ... under the direction of Roger Beachy , Ph.D., ... the Danforth Plant Science Center, and is used to ...
(Date:9/18/2014)... Sept. 18, 2014  Neogen Corporation (Nasdaq: ... a strategic agreement with Merck Animal Health to market ... The Igenity Dairy Heifer Program consists of genomic ... the genetic potential of replacement dairy heifers. The genomic ... born, and is an excellent tool in the decision-making ...
(Date:9/18/2014)... Pennsylvanie, 18 septembre 2014 Mapi, ... en 1974, a été depuis 40 ans ... évaluations cliniques traditionnelles par des évaluations recentrées ... sur les impacts économiques des traitements. ... A cours d,une récente conférence ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2Merck Animal Health to market Neogen's dairy genomic program 21974 - 2014 - Mapi fĂȘte ses 40 ans 2
... 7 Amsterdam Molecular,Therapeutics (Euronext: AMT), a leader ... the treatment of the first patient in a ... targets,lipoprotein lipase deficiency (LPLD), a seriously debilitating and,potentially ... randomized controlled trial has been designed to gather ...
... Kendle (Nasdaq: KNDL ), a leading, global ... or $0.06 per share for the first quarter 2009 compared ... share for the first quarter 2008. On a pro forma ... $0.47 per diluted share compared with $0.38 per diluted share ...
... Amgen (Nasdaq: AMGN ), today announced ... Stockholders, held at The St. Regis Hotel, San Francisco, ... represented at the meeting.The director nominees: David Baltimore, Frank ... Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer, ...
Cached Biology Technology:AMT Starts Preregistration Trial for Glybera(TM) 2AMT Starts Preregistration Trial for Glybera(TM) 3Kendle Announces First Quarter 2009 Results 2Kendle Announces First Quarter 2009 Results 3Kendle Announces First Quarter 2009 Results 4Kendle Announces First Quarter 2009 Results 5Kendle Announces First Quarter 2009 Results 6Kendle Announces First Quarter 2009 Results 7Kendle Announces First Quarter 2009 Results 8Amgen Announces Voting Results Of Annual Meeting Of Stockholders 2
(Date:9/19/2014)... A new study shows that legume plants regulate ... cytokininssignaling molecules that are transmitted through the plant ... the number of bacteria-holding nodules in the roots. ... the National Institute for Basic Biology, the Graduate ... Center for Sustainable Resource Science in Japan. ...
(Date:9/18/2014)... A sleep-promoting circuit located deep in the primitive brainstem ... by researchers at Harvard School of Medicine and the ... this is only the second "sleep node" identified in ... necessary and sufficient to produce deep sleep. , Published ... study demonstrates that fully half of all of the ...
(Date:9/18/2014)... robotic system that can operate inside the bore of ... of a biomedical research partnership program at Brigham and ... if the robot, in conjunction with real-time MRI images, ... costly, and less discomforting for the patient. The novel ... therapies with greater precision. , Developed by a team ...
Breaking Biology News(10 mins):For legume plants, a new route from shoot to root 2No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... harnessing of 'T-rays' - electromagnetic terahertz waves - which ... varied as biological cell abnormalities and explosives has been announced. ... in Spain have said they have found a way to ... Their findings are set out in a letter published in ...
... heart is removed, the dynamic interplay between a mass ... the protective cell layer that covers the wound spurs ... Medical Center scientists have found. , The scientists further ... the cell mass and the protective covering, encouraging the ...
... Institute of Virology and Immunology (GIVI) have identified a previously ... HIV, a finding that may lead to new approaches for ... Oct. 2, 2006, in Proceedings of the National Academy of ... laboratory of GIVI Director Warner C. Greene, MD, PhD, explains ...
Cached Biology News:T-ray breakthrough could make detecting disease far easier 2Key to zebrafish heart regeneration uncovered 2Key to zebrafish heart regeneration uncovered 3Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G 2
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
...
Mouse monoclonal [CAT-2] to Chloramphenicol Acetyltransferase...
Recommended fro Western blotting application...
Biology Products: